共 32 条
- [21] ALX-0600, a dipeptidyl peptidase-IV resistant glucagon-like peptide-2 (GLP-2) analog, improves intestinal function in short bowel syndrome (SBS) patients with a jejunostomyGASTROENTEROLOGY, 2002, 122 (04) : A191 - A192Jeppesen, PBBlosch, CMLopansri, JBSanguinetti, ELBuchman, ALScolapio, JLZiegler, TRHoward, LMortensen, PB
- [22] The effects of glucagon-like peptide 2 (GLP-2) on intestinal mucosal blood flow evaluated in the stoma nipple by laser Doppler flow in short bowel patientsGASTROENTEROLOGY, 2006, 130 (04) : A602 - A602Hoeyerup, PeterSchmidt, Peter T.Hellstrom, PerMortensen, Per B.Jeppesen, Palle B.
- [23] Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled studyREGULATORY PEPTIDES, 2013, 184 : 30 - 39Madsen, K. B.Askov-Hansen, C.Naimi, R. M.Brandt, C. F.Hartmann, B.Holst, J. J.Mortensen, P. B.Jeppesen, P. B.
- [24] EFFECTS OF SHORT-TERM TREATMENT WITH GLEPAGLUTIDE, A LONG-ACTING GLUCAGON-LIKE PEPTIDE-2 ANALOG, ON INTESTINAL MORPHOLOGY AND CITRULLINE IN PATIENTS WITH SHORT BOWEL SYNDROMEGASTROENTEROLOGY, 2018, 154 (06) : S160 - S160Naimi, Rahim M.Hvistendahl, MarkPoulsen, Steen S.Kissow, HannelouiseAndreasen, Rasmus H.Hansen, Mark B.Jeppesen, Palle B.
- [25] Teduglutide, A Novel Analog of Glucagon-like Peptide 2 (GLP-2), Is Effective and Well Tolerated in Reducing Parenteral Support (PS) Volume in Short Bowel Syndrome-Intestinal Failure (SBS-IF) Subjects: Results from a 24-week, Placebo-Controlled Phase 3 TrialAMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S97 - S97O'Keefe, StephenJeppesen, PallePertkiewicz, MarekSeidner, DouglasHeinze, HartmutJoelsson, Bo
- [26] EFFECT OF GLEPAGLUTIDE, A LONG-ACTING GLP-2 ANALOG, ON HEPATIC, RENAL AND BONE MARKERS IN PATIENTS WITH SHORT BOWEL SYNDROME: RESULTS OF EASE SBS-1 PHASE 3 TRIALGASTROENTEROLOGY, 2024, 166 (05) : S1714 - S1715Mercer, David F. F.Vanuytsel, TimSubramanian, SukanyaJoly, FranciscaWanten, GeertLamprecht, GeorgKunecki, MarekRahman, FarooqNielsen, Thor S. S.Graff, Lykke BjerglundHansen, Mark B.Pape, UlrichJeppesen, Palle B.
- [27] The REVE study, preliminary results. A Monocentric Single-arm study to characterize the long-term safety, efficacy, and pharmacodynamic of GLP-2 analog (Revestive®) in the management of short bowel syndrome pediatric patients on home-parenteral nutrition (HPN).TRANSPLANTATION, 2019, 103 : S11 - S11Lambe, CecileTalbotec, CecileKapel, NathaliePiketty, MarieGoulet, Olivier
- [28] Teduglutide, a Novel Analogue of Glucagon-like Peptide 2 (GLP-2), Is Effective and Safe in Reducing Parenteral Support Volume in Short Bowel Syndrome-Intestinal Failure Subjects: Results From a 24-Week, Placebo-Controlled Phase 3 Trial (STEPS)GASTROENTEROLOGY, 2011, 140 (05) : S146 - S146Jeppesen, Palle B.Pertkiewicz, MarekSeidner, Douglas L.O'Keefe, StephenHeinze, HartmutJoelsson, Bo
- [29] PARENTERAL SUPPORT WEANING, CLINICAL BENEFIT AND IMPROVED PATIENT REPORTED OUTCOMES IN SHORT BOWEL SYNDROME INTESTINAL FAILURE (SBS-IF) PATIENTS WITH COLON-IN-CONTINUITY (CIC) TREATED WITH THE LONG-ACTING GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOG APRAGLUTIDEGASTROENTEROLOGY, 2024, 166 (05) : S880 - S880Verbiest, AstridHvistendahl, Mark K.Bolognani, FedericoLi, CarrieYoussef, Nader N.Jeppesen, Palle B.Joly, FranciscaVanuytsel, Tim
- [30] GLEPAGLUTIDE, A LONG-ACTING GLP-2 ANALOG, SIGNIFICANTLY REDUCES NEED FOR PARENTERAL SUPPORT IN PATIENTS WITH SHORT BOWEL SYNDROME: RESULTS OF EASE SBS-1, A RANDOMIZED, DOUBLEBLIND, 24-WEEK PHASE 3 TRIALGASTROENTEROLOGY, 2023, 164 (06) : S151 - S151Mercer, David F. F.Vanuytsel, TimSubramanian, SukanyaJoly, FranciscaWanten, GeertLamprecht, GeorgKunecki, MarekRahman, FarooqRonn, Birgitte BiilmannGraff, Lykke BjerglundBerner-Hansen, MarkPape, UlrichJeppesen, Palle B.